NGEN Stock Overview
Engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NervGen Pharma Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$3.00 |
52 Week High | CA$3.98 |
52 Week Low | CA$1.65 |
Beta | 1.44 |
1 Month Change | 33.93% |
3 Month Change | 9.49% |
1 Year Change | 44.93% |
3 Year Change | 14.07% |
5 Year Change | 71.43% |
Change since IPO | 72.41% |
Recent News & Updates
Recent updates
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Oct 23We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow
Jun 11Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?
Dec 22Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation
Aug 30Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?
Apr 04NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate
Feb 02We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Nov 23We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully
Jun 29We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Mar 16We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate
Mar 08Shareholder Returns
NGEN | CA Pharmaceuticals | CA Market | |
---|---|---|---|
7D | 9.9% | -1.2% | -3.7% |
1Y | 44.9% | -24.4% | 15.0% |
Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -24.4% over the past year.
Return vs Market: NGEN exceeded the Canadian Market which returned 15% over the past year.
Price Volatility
NGEN volatility | |
---|---|
NGEN Average Weekly Movement | 13.4% |
Pharmaceuticals Industry Average Movement | 12.0% |
Market Average Movement | 8.2% |
10% most volatile stocks in CA Market | 17.6% |
10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: NGEN's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: NGEN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | n/a | Mike Kelly | www.nervgen.com |
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.
NervGen Pharma Corp. Fundamentals Summary
NGEN fundamental statistics | |
---|---|
Market cap | CA$220.06m |
Earnings (TTM) | -CA$24.01m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.8x
P/E RatioIs NGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NGEN income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$24.01m |
Earnings | -CA$24.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.34 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/20 02:05 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NervGen Pharma Corp. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Chelsea Stellick | iA Capital Markets |
Scott McAuley | Paradigm Capital, Inc. |
Justin Keywood | Stifel Canada |